Recently, Qilu Stem Cell Treatment Co., Ltd. smoothly passes the review of high and new technology, whose certification of high and new tech enterprise smoothly extends to December of 2018.

In accordance with the latest regulations of Guidance for the Determination and Management of High and New Tech Enterprises of 2016, the financial department of cell treatment company works with all departments to organize and  compile the review materials carefully and finally obtains the qualification of high and new tech enterprise through two rounds of on-site verification of relevant departments. The high and new tech enterprise refers to the resident enterprise that keeps conducting research,  development and transformation of technical achievements, forms the core proprietary intellectual property rights of the enterprise and launches the operational activities on such basis within the High and New Tech Fields with the Government's Primary Support, which has registered for more than one year within the territory of China (excluding areas of HongKong, Macao and Taiwan). It is the knowledge-intensive and technology-intensive economic entity. Obtaining of the High and New Tech Enterprises qualification can not only reduce the taxes for the enterprises but also mean the approval for the research and development technology and capability of the enterprises.

Passing of the High and New Tech Enterprises review this time offers the platform for the R&D technology research and innovation of the Qilu Stem Cell Treatment Co., Ltd., which also plays an important role on the enhancement of the external publicity and business expansion to the company.